INM
NasdaqCMInMed Pharmaceuticals Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 39 recent filings. 5 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
ADAR1 Capital Management, LLC 10% Owner | Buy (open market) | 1K | $1.56 | $1,555.00 | 2026-07-15 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 4.88K | $1.55 | $7,567.10 | 2026-07-14 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 493 | $1.55 | $764.15 | 2026-07-14 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 13.76K | $1.55 | $21,329.55 | 2026-07-15 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 1.39K | $1.55 | $2,152.95 | 2026-07-15 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 19 | $1.55 | $29.45 | 2026-07-16 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 2 | $1.55 | $3.10 | 2026-07-16 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 545 | $1.54 | $839.30 | 2026-06-30 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 55 | $1.54 | $84.70 | 2026-06-30 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 3.95K | $1.55 | $6,116.30 | 2026-07-01 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 398 | $1.55 | $616.90 | 2026-07-01 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 1.46K | $1.55 | $2,263.00 | 2026-07-02 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 147 | $1.55 | $227.85 | 2026-07-02 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 51.06K | $1.56 | $79,647.36 | 2026-05-20 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 5.15K | $1.56 | $8,040.24 | 2026-05-20 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 30.88K | $1.69 | $52,190.58 | 2026-05-21 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 3.12K | $1.69 | $5,269.42 | 2026-05-21 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 16.16K | $1.57 | $25,377.48 | 2026-05-29 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 1.63K | $1.57 | $2,562.24 | 2026-05-29 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 14.84K | $1.55 | $22,998.90 | 2026-06-01 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 1.5K | $1.55 | $2,321.90 | 2026-06-01 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 20.75K | $1.52 | $31,544.56 | 2026-06-02 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 2.1K | $1.52 | $3,184.40 | 2026-06-02 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 7.07K | $1.55 | $10,956.95 | 2026-06-03 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 714 | $1.55 | $1,106.70 | 2026-06-03 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 6.13K | $1.57 | $9,616.25 | 2026-06-04 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 618 | $1.57 | $970.26 | 2026-06-04 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 49.97K | $1.57 | $78,446.62 | 2026-06-05 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 5.05K | $1.57 | $7,920.65 | 2026-06-05 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 29.52K | $1.52 | $44,867.36 | 2026-06-08 |
Vivo Opportunity, LLC 10% Owner | Buy (open market) | 2.98K | $1.52 | $4,532.64 | 2026-06-08 |
ADAR1 Capital Management, LLC 10% Owner | Buy (open market) | 68.55K | $1.60 | $109,667.89 | 2026-05-19 |
ADAR1 Capital Management, LLC 10% Owner | Buy (open market) | 200K | $1.56 | $312,080.00 | 2026-05-19 |
ADAR1 Capital Management, LLC 10% Owner | Buy (open market) | 200K | $1.50 | $299,800.00 | 2026-05-19 |
Johnson Shane Aaron Sr VP & General Manager | Grant / award | 8.5K | $0.00 | — | 2025-12-19 |
Lemerond Nicole Director | Grant / award | 1.75K | $0.00 | — | 2025-12-19 |
Klompas Neil A Director | Grant / award | 1.75K | $0.00 | — | 2025-12-19 |
Jagpal Netta Chief Financial Officer | Grant / award | 18K | $0.00 | — | 2025-12-19 |
WOUDENBERG MICHAEL Chief Operating Officer | Grant / award | 18K | $0.00 | — | 2025-12-19 |
Source: SEC EDGAR Forms 4/4A (CIK 1728328). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$INM ANOTHER @APEDM LOsER PUMPER ALERT
$INM The Daily Cost Is Punishing: A 197% annual fee means short sellers are paying roughly 0.54% of their total position value every single day just to hold the short open.Extreme Squeeze Risk: Because the daily fees drain a short seller's capital so rapidly, any positive headline regarding the Mentari Therapeutics merger filings or their Alzheimer’s disease program (INM-901) could force short sellers to panic-buy shares to exit, triggering a violent upward short squeeze.Micro-Cap Trap: INM is a micro-cap stock with a market value of roughly $6 million to $9 million. Because the "float" (the number of shares available to the public to trade) is incredibly small, even a minor wave of retail buying volume can cause the stock price to spike unpredictably.
$INM $MSTR $INTC
$INM
$INM 😏
$INM patience 😉
$WBUY $INM $ZCMD after hour 👁️👁️ high interest rate and weekend. Short will pay 💰
$WBUY $ZCMD $INM high short interest with low float & no short share available. They are using dark pool short I guess so this high interest nobody like to pay so after hour will be nice play. I am holding small position all of them.
$INM Not many shares left to short are there?
$INM one trader just bought 19K shares $1.87, doubt they did that just for the fun of it, the manipulator creeps that shorted this below two bucks, better stay on their toes.
$INM buyside pressures have been building up for the past hour, fools stacking the offer, hopefully theyre shorters that get blown up over two bucks.
$INM are we going up or what ? need volume
Latest news
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
InMed Pharmaceuticals Amends Deal With Mentari Therapeutics
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
/C O R R E C T I O N -- InMed Pharmaceuticals/
InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM)
BC-Most Active Stocks
A migraine drugmaker heads to the public markets through reverse merger
InMed Pharmaceuticals Amends Preferred Investment Options
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.